Introduction
The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive condition presenting classically in childhood with immunodeficiency, eczema, and thrombocytopenia. 1, 2 Affected males rarely survive beyond age 20, with opportunistic infection and hemorrhage the most frequent causes of death. Hematopoietic stem cell transplantation is curative for WAS. [3] [4] [5] However, most patients lack matched sibling donors, and transplant using matched unrelated donors is effective only in a subset of patients. 6 Alternative methods, such as gene therapy, therefore warrant exploration.
WAS is caused by mutations in the WAS gene, which encodes a protein (WASP) that normally integrates and transmits signals that originate at the cell membrane and result in cytoskeletal rearrangements. 7, 8 WASP functions primarily by catalyzing actin polymerization at new branch points on pre-existing actin polymers, a process termed 'dendritic nucleation'. 9 WASP is expressed only in blood cells. A homologue, N-WASP, is expressed in other tissues and in some lymphocyte populations.
While in vitro dysfunction of several cell types derived from WAS patients, including B cells, macrophages, and dendritic cells, has been demonstrated, T-cell dysfunction is thought to be central to the immunodeficiency. WAS-derived T-cell lines fail to proliferate or secrete cytokines normally after T-cell receptor stimulation. 10, 11 This is thought to be because of the defective formation of the 'immunologic synapse', a cup-shaped projection of the T-cell membrane, which stabilizes the interaction between T cells and antigen-presenting cells. In support of the critical role of T-cell dysfunction in WAS, two recent reports of clinical improvement in patients whose peripheral T cells had been partially repopulated by spontaneous revertant wild-type populations suggest that gene-corrected T cells have a significant, and efficacious, proliferative advantage over WASP-deficient cells. 12, 13 Both patients survived longer than would be otherwise expected, and in one patient clinical improvement was attributed to emergence of the revertant T-cell population. Efforts at correction of T-cell function by gene transfer are therefore a logical first step toward genetic correction of WAS.
Previous studies utilizing gene transfer in B-cell lines from WAS patients have demonstrated increased actin polymerization 14 and normalization of the glycosylation state of a membrane protein. 15 Introduction of human WASP into dendritic cells derived from WAS patients showed improved podosome formation. 16 Impaired phagocytosis by macrophages derived from WAS knock-out mice was also improved by the expression of human WASP. 17 However, aberrant actin polymerization was seen when WASP expression was achieved by retroviralmediated gene transfer in epithelium-derived cell lines, which do not normally express the protein. 18, 19 Here, we report our efforts to use oncoretroviral vector-mediated WASP expression to correct the functional defects in primary T cells derived from WAS patients.
Results
Correction of the proliferative defect in WAS T lymphocytes by oncoretroviral-vector-mediated transfer of the WASP gene
The design of the MSCV-WASP-GFP (MWG) vector ( Figure 1 ) results in inclusion of the WASP and GFP coding sequences in a bicistronic transcript separated by the internal ribosomal entry signal (IRES) from the encephalomyelitis virus, giving confidence that the WASP was expressed in GFP + cells. The mouse stem cell virus (MSCV) long terminal repeat promoter in this context promotes a high level, persistent gene expression in hematopoietic cells. 20, 21 We pseudotyped the vector particles with the RD114 envelope protein in the light of our preliminary results indicating that this approach yields improved efficiency of transduction of human T cells. Specifically, we found that RD114-pseudotyped, GFP-expressing vector preparations yielded over 10- In a second experiment, improved transduction methods (see Materials and Methods) resulted in the higher transduction rates shown in Figure 1 . After 9 days of expansion in IL2-containing medium, flow cytometry demonstrated that over 92% of the cells were T cells expressing CD4 or CD8, and that the two subsets had been transduced with comparable efficiency (Table 2) . After further expansion for 2 days in IL2-containing media, a fraction of the cells were harvested and protein extracts prepared. Western blot analysis demonstrated expression of WASP at levels that were somewhat lower Transduced cells were cultured in IL2-containing medium and exposed to immobilized anti-CD3 antibody for 48 h periods on days 3-5, 6-8, and 10-12.
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than those observed in control cells without transduction ( Figure 1 ). Analysis was performed with two different loadings of extract from patient and control cells, and quantification of WASP compared to the actin control was performed by densitometry and corrected for the percent of GFP + cells. The amount of WASP in GFP + cells of patient 2 was estimated to be 80% and of patient 3 to be 50%, the levels found in normal T cells. No WASP was detected in the mock-or MG-transduced cells ( Figure 1 ).
The proliferative response of the three patients' gene corrected cells to anti-CD3 was substantially enhanced compared to that of their control cells ( Figure 2 ). The [ 3 H]thymidine incorporation by the gene corrected cells of patients 2 and 3 was more than 10-fold higher than that of mock-or MSCV-GFP-transduced patient cells (Figure 2b ). The smaller difference between MG-transduced and MWG-transduced cells of patient 1 was most likely because of the greater amount of anti-CD3 antibody (50 ng/well versus 5 ng/well) used to stimulate this patient's cells. A similar convergence of the control and WASP-expressing cells was seen for patients 2 and 3 as the amount of anti-CD3 antibody used per well was increased to 50 ng/well, and at still higher levels (500 ng/well) the two proliferative responses were indistinguishable (data not shown). The proliferative response of both control and gene-modified WAS cells from the three patients to IL-2 was 50% or more than that of normal control cells (data not shown).
WAS cells exhibit augmented IL2 production following gene correction
IL2 secretion, an important element of T-cell function, is deficient in patients with WAS. The proportion of cells 
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proliferative response and partial correction of the defective cytokine secretion, without apparent toxicity. Our results also illustrate the utility of vector particles pseudotyped with the RD114 envelope protein for transducing lymphocytes, similar to the utility of RD114 pseudotyped particles for transduction of human CD34 + cells from umbilical cord blood. 22 In previous studies in which the WAS gene was introduced into B-cell lines, oncoretroviral vectors pseudotyped with the GALV envelope protein were used.
14, 15 The low transduction rates attained with this method required the use of a neomycin phosphotransferase gene and subsequent selection in G418 containing media in order to yield cultures in which most of the cells expressed WASP. The high transduction rate we achieved with RD114-pseudotyped vector particles allowed us to avoid the use of drug selection and, consequently, allowed us to study primary T cells after short-term culture rather than transformed cell lines.
Our results clearly show that WASP expression in WAS-derived primary T cells has a corrective effect on both the proliferation defect and the defective cytokine secretion seen in TCR-stimulated, WAS-derived T cells. Since these functional deficits are thought to be central to the immunodeficiency of WAS, our results suggest that correction of the immunodeficiency by in vivo expression of wild-type WASP could be feasible. Similar corrective effects of engineered WASP expression in B-cell lines, 14, 15 macrophages, 17 and dendritic cells 16 lend support to the idea that the functional deficits seen in WAS can be corrected without the normal mechanisms that modulate the levels of WASP mRNA. Partial correction of the IL2 secretory defect and more complete correction, compared to control cells, of the mitogenic response to TCR stimulation was observed in primary T cells in our studies. The cytokine assay reflects a brief (5 h) period of stimulation in which the response may be quantitatively dependent on WASP concentration. The mitogenic assay is more complex in that during the 72 h of stimulation there is both a proliferative response as well as the potential for a secondary apoptotic response to the combination of exogenous TCR and autocrine IL2 stimulation. 23 After this material was submitted for publication, Wada et al 29 described similar results in immortalized Tcell lines or drug selected (G418) primary T cells from WAS patients. Biochemical studies demonstrated normal interaction of vector-encoded WASP with the SH3 domains of Grb2, PLC-g1, and Fyn. Stimulation of gene corrected, immortalized T cells induced actin polymerization and drug selected, primary T cells from two patients were shown to proliferate in response to anti-CD3 stimulation. Our results complement and extend these data in that we achieved a high efficiency of gene transfer with RD114 pseudotyped vector particles allowing study of primary T-cell populations without drug selection of transduced cells. Mitogenesis of gene corrected, primary T cells in response to anti-CD3 was demonstrated for three patients and improved cytokine production was demonstrated by the cells of the two patients studied. Our work enhances the feasibility of using gene corrected, primary T cells to treat established, chronic infections such as molluscum contageosum or herpes simplex in WAS patients as suggested by Wada et al 29 However, the high incidence of autoimmune disease in WAS patients raises the possibility that gene correction of peripheral T cells could augment the activity of undesirable self-reactive clones, an issue that deserves careful appraisal in murine WAS in advance of any clinical trial of this method. Ultimately, the relevance of correction of such T-cell responses must be evaluated in vivo. Murine models of WASP deficiency have been developed, 24, 25 and recent results in our laboratory have shown that the phenotype can be corrected by stem cell transplantation. 26 Further, we have shown that WASP-deficient mice have impaired defenses against mycobacterial infection and secondary influenza challenge (Strom T, Lang R, and Turner S, unpublished observations). The ability to improve WASP-deficient T-cell function by oncoretroviral vectormediated gene transfer and expression provides encouragement for testing the efficacy of stem cell targeted gene transfer in the murine model, in which correction of the immunodeficiency can be evaluated in terms of susceptibility to mycobacterial or viral infection.
Materials and methods

Oncoretroviral vectors
The coding region of the human WASP cDNA was amplified using a commercially available cDNA library and inserted into a Bluescript SK vector before insertion upstream of the IRES element of an MSCV/IRES/GFP vector, 21 yielding plasmid pMWG. VSV-G pseudotyped oncoretroviral vector preparations were prepared by cotransfection of 293 T cells with plasmid pMWG (Figure  1 ) or plasmid MG (encoding GFP with no IRES), and the packaging plasmids pEQPAM3-E and pSRaG. The resultant vector preparations were used to transduce FLYRD18 cells. 27 Pools of transduced FLYRD18 cells were used as a source of vector particles for the transduction of peripheral blood-derived lymphocytes and of Jurkat cells. The vector genome was shown to be unrearranged by Southern blot analysis. Conditioned media containing vector particles were titered on HeLa cells by evaluating the percentage of GFP-positive cells achieved with several dilutions of the vector preparation. The vector preparations had titers ranging from 0.5 to 2.0 Â 10 6 /ml. For functional comparison of RD114 to the amphotrophic envelope protein, the MGirL22Y vector was used to construct either an amphotrophic (PA317-derived) producer cell line or aFLYRD18-derived producer line, respectively, as described above.
Cell culture and transduction
The studies using patient and control cells were reviewed and approved by the Institutional Review Board. For patient 1 and control, peripheral blood mononuclear cells were prepared by Ficoll step-gradient, and stimulated for 48 h with PHA ('1X', Life Technologies) and IL2 (300 U/ml; Chiron) in RPMI containing 10% inactivated fetal bovine serum (iFBS). The cells were then grown for 4 days in RPMI containing IL2 only. Transduction was then performed in tissue-culture treated, 12-well dishes pretreated with Retronectin s (Takara; 100 mg/ml in PBS) for 2 h at room temperature. Upon removal of the retronectin solution, wells were treated with 2% bovine serum albumin (BSA, fraction V,
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Sigma) in PBS for 30 min at room temperature. This solution was removed and a conditioned medium containing vector particles (5 Â 10 5 to 1.5 Â 10 6 infectious units/ml) was added at 1 ml/dish and incubated for 30 min at room temperature. The preloading of vector particles was repeated, after which the vector-depleted medium was removed and replaced with approximately 9 Â 10 5 cells in RPMI (1.5 ml/well) containing 10% iFBS. Adsorption/transduction was allowed to take place overnight, after which the cells were scraped off the dish and expanded in RPMI/10% iFBS containing human IL2 (300 U/ml). Control cells obtained from a normal volunteer were processed in parallel and identical to patient cells.
For patients 2 and 3, peripheral blood mononuclear cells were prepared by Ficoll step-gradient, resuspended in RPMI/20% iFBS/10% DMSO, frozen on dry ice, and stored in liquid nitrogen. Again, control cells from a normal volunteer were processed concurrently and identically. Upon thawing, the cells were stimulated for 48 h with PHA and IL2 (as for patient 1), then transduced immediately in nontissue culture treated, six-well dishes pretreated with Retronectin s as for patient 1. After BSA treatment, a conditioned medium containing 1.7-1.9 Â 10 6 vector particles (2-3 ml/well) was added and incubated once only for 30 min at room temperature. The vector-depleted medium was removed and approximately 1.0 Â 10 6 cells were added per well. Overnight transduction and subsequent expansion were as described for patient 1. The higher transduction rate achieved with the cells of patients 2 and 3 compared to patient 1 may have reflected the fact that transduction was performed immediately after PHA/IL2 stimulation, conditions that were found with control cells to increase transduction frequency compared to the interval expansion, with IL2 only, used in the case of patient 1. In addition, noncoated plates were used, and the ratio of adsorbed vector particles to cells undergoing transduction was higher for patients 2 and 3.
For both groups, expansion of the cells after transduction was performed at 1-2 million cells per square centimeter of tissue culture container. For patient 1, a low transduction rate was compensated by intermittently growing the T cells (and control cells) in wells coated with anti-CD3 antibody (2.5 mg/ml in PBS, overnight, 41C). Cells were grown in treated wells for 48 h in RPMI/ 10% iFBS, followed by growth for 24-48 h in RPMI/10% iFBS/IL2. This procedure was repeated three times.
Transduction efficiency in all cases was assessed by flow cytometric detection of GFP expression.
Gene expression and functional assays
Western blotting was performed by standard methods using the anti-human WASP antibody described by Stewart et al 28 a kind gift of Dr David L Nelson. Proliferation assays were performed in triplicate in round-bottomed 96-well dishes. Prior to the assay, antiCD3e antibody (Pharmingen) was bound to the wells at 41C, overnight. Cells that had been growing in IL2-containing media were shifted to RPMI/10%iFBS lacking IL2. The next morning the wells were rinsed with PBS and 2 Â 10 5 cells were transferred to each well in fresh PBS/10% iFBS. The cultures were incubated for 48 h after which 1 mCi/well methyl [ IL-2 secretion was assayed via intracellular cytokine staining. Prior to the assay, round-bottomed, 96-well dishes were coated with anti-CD3e antibody and cells were shifted to media lacking IL2 as for the proliferation assays. Cells (2 Â 10 5 ) were transferred to each well in a fresh PBS/10% iFBS containing 10 mg/ml Brefeldin-A (Epicentre Technologies). The cultures were incubated for 5 h. After binding of PE-tagged anti-CD4 (Pharmingen), the cells were permeabilized, and APC-tagged anti-IL2 antibody was bound, using the Fix&Perm kit (Caltag) as per the manufacturer's instructions. Cells were then analyzed by flow cytometry. We chose to use the intracellular cytokine staining assay rather than an ELISA because preliminary results with an ELISA suggested that reabsorption of IL2, which could be blocked by an antireceptor antibody, made quantitative interpretation difficult because of the potential for antibody-mediated receptor stimulation.
